



Case Report

Aggressive fibromatosis of head and neck: Considerations on the optimal treatment method on the basis of case report



Wacław Kopala^{a,*}, Marcin Siniarski^a, Sylwia Grzybowska^b, Maciej Pietrzak^a,
Grażyna Poniadowska-Broniek^c, Andrzej Kukwa^b

^a Department of Otolaryngology, Provincial Specialist Children's Hospital in Olsztyn, Poland

^b Department of Otolaryngology, Clinical University Hospital in Olsztyn, Poland

^c Department of Pathology, Provincial Specialist Children's Hospital in Olsztyn, Poland

ARTICLE INFO

Article history:

Received 15 December 2015

Received in revised form 3 January 2016

Accepted 28 May 2016

Available online 28 February 2017

Keywords:

Aggressive fibromatosis

Head and neck

Surgery

Chemotherapy

Children

ABSTRACT

Introduction: The term fibromatosis refers to proliferation of fibrous tissue in the form of irregular nodules or soft tissue sarcoma. It is characterized by local malignancy with tendency to recurrence, significant hypertrophy of the mature connective tissue and lack of the ability to form distant metastases. Pathological lesions originate from fascial, muscle and tendinous tissue.

Aim: The aim of this work is to analyze the efficacy and safety of the selected methods of treatment of aggressive fibromatosis on the basis of the presented case.

Case study: A five-year-old boy was admitted to the Department of Otolaryngology of the Provincial Specialist Children's Hospital in Olsztyn due to right sided cervical mass. Histological examination of biopsy material revealed aggressive fibromatosis. The child was previously treated for two years with systemic chemotherapy with methotrexate, vinblastine, vincristine, imatinib and tamoxifen with no improvement. Surgical tumor removal was performed on February 14, 2014. During the 18-month observation period no signs of tumor recurrence were observed.

Results and discussion: In the treatment of aggressive fibromatosis various therapeutic methods are used, including radiotherapy, chemotherapy and surgery. The effects of chemotherapy and radiotherapy are frequently unsatisfying. These methods are associated with numerous complications and side effects, thus mode of treatment should be considered individually for each patient. In case of the presented patient surgical tumor removal was the best and the most effective treatment method.

Conclusions: Surgery should be a treatment of choice, whereas chemotherapy and radiotherapy should be considered as alternative or complementary methods in the treatment of aggressive fibromatosis.

© 2016 Warmińsko-Mazurska Izba Lekarska w Olsztynie. Published by Elsevier Sp. z o.o. All rights reserved.

Introduction

The term fibromatosis refers to a wide group of fibroplastic lesions which present as low grade soft tissue sarcoma. They are characterized by local aggressiveness with a tendency to local recurrence, significant hypertrophy of mature connective tissue with formation of conglomerate of nodules and lack of the ability to form distant metastases. In English literature it is known as aggressive fibromatosis (AF) or desmoid tumor, distinguished by deep location.¹

Histologically, typical features of fibromatosis include excessive proliferation of homogeneous slender spindle cells infiltrating the adjacent tissue. They are surrounded by collagen stroma with visible vessels. These cells show no atypia and their mitotic index may vary within broad limits. Number of mitoses may be focally high, which does not imply malignancy. Pathological lesions originate from fascial, muscle and tendinous tissue.^{1,2}

Correlation between injury and AF was revealed in 19%–49% of cases. There is a theory that its pathogenesis is associated with an abnormal wound healing process with proliferation of immature fibroblasts, which subsequently leads to tumor formation. The role of sex hormones in pathogenesis of AF is also emphasized.^{2,3}

Depending on the location of lesion fibromatosis was divided into two clinical types: superficial and deep. The most common type of superficial fibromatosis is palmar fibromatosis, called Dupuytren's contracture. Other typical locations of superficial AF

* Correspondence to: Department of Otolaryngology, Provincial Specialist Children's Hospital in Olsztyn, Żołnierska 18 A, 10-561 Olsztyn, Poland. Tel.: +4889 539 34 30.

E-mail address: wkopala@onet.pl (W. Kopala).

include feet and penis.⁴ Deep fibromatosis most frequently locates in the abdominal wall, typically in straight abdominal or internal oblique muscle. Deep AF constitutes approximately 3% of soft tissue tumors, and there are 2–4 new cases per 1 million people each year. Intraabdominal form locates in the mesentery and pelvis minor. Mesenteric fibromatosis is associated with Gardner's syndrome.⁵

Typical extra-abdominal locations include shoulder, chest wall, back, thigh, head and neck. In case of extra-abdominal locations predominant symptom is poorly demarcated deep-seated tumor. Other symptoms include edema and pain associated with infiltration of the adjacent structures and organs. Probability of the occurrence of AF of the head and neck is almost equal for both sexes. Although AF does not tend to metastasize, in case of head and neck location course of the disease may be unfavorable and lead to serious complications, including death.^{6–8}

2. Aim

The aim of this work was to analyze the efficacy and safety of the selected methods of treatment of AF on the basis of the presented case.

3. Case study

Male child aged 5 years 4 months was admitted to the Department of Otolaryngology of the Provincial Specialist Children's Hospital in Olsztyn due to right sided cervical mass for surgical treatment. At the age of 2.5 years he was diagnosed with right sided cervical tumor which presented after upper respiratory tract infection. Magnetic resonance imaging (MRI) of the neck conducted in September 2011 revealed an abnormal tissue mass with irregular borders in the right submandibular area. The dimension of the tumor was $5.3 \times 2.9 \times 4.4$ cm. The lesion was posteriorly directly adjacent to cervical vessels, not infiltrating them, while medially it reached parapharyngeal space (Fig. 1).

Material collected during aspiration biopsy revealed nodular fasciitis. In January 2012 open biopsy of the tumor was performed and diagnosis of AF was established (report no. 8352/2012 dated February 8, 2012, Department of Pathology, Medical University of Wrocław). In November 2012 chemotherapy with methotrexate and vinblastine was initiated, and overall 10 courses were administered. The treatment was completed in January 2013. No

clinical improvement was observed and MRI revealed slight progression of the tumor.

In March 2013 another chemotherapy was started. Vincristine was used but after the third course the treatment was discontinued due to gastrointestinal complications. From May 2013 patient was treated with imatinib (Glivec) and from November 2013 with tamoxifen. After tamoxifen slight regression of the tumor was observed, confirmed in MRI of the neck. Due to unsatisfying effects of conservative treatment patient was qualified for surgery (Fig. 2).

Surgical tumor removal was performed on February 14, 2014 (Prof. A. Kukwa). The procedure involved incision along the sternocleidomastoid muscle, dissection entirely within healthy tissue of the tumor penetrating in the region of large cervical vessels and lateral pharyngeal wall. Entire submandibular gland was also removed. During postoperative period House-Brackman Grade III paresis of the lower branch of the facial nerve and difficulty swallowing solid foods were observed within first days after surgery and resolved spontaneously. Patient was discharged home in good general condition on the 12th postoperative day and remains in follow-up (Fig. 3).

Histological examination (report no. K91/14 dated March 17, 2014, Department of Pathology, Institute of Mother and Child in Warsaw) confirmed previous diagnosis of AF (*fibromatosis p. desmoides*) (Figs. 4 and 5).

Control MRI of the neck after surgery was performed three times, last in June 2015 and showed no tumor recurrence (Fig. 6).

4. Results and discussion

In the management of AF surgical removal of the tumor with a margin of healthy tissue is a treatment of choice. However, it is not always possible due to tumor sizes, penetration to adjacent structures and tissues, as well as macroscopically unclear margin of the tumor. Local recurrences after AF resection in the head and neck region are estimated at 40%–70%. The majority of recurrences are observed within 18 months post surgery.⁹



Fig. 1. MRI of the neck before surgical treatment. Visible large right sided tumor enhanced after contrast infusion.



Fig. 2. Patient before surgery. Visible large asymmetry of the right neck caused by the presence of the tumor.



Fig. 3. Patient 16 months after surgery. Visible slight paresis of the lower branch of right facial nerve.




Fig. 4. Clusters of characteristic homogeneous, slender spindle cells surrounded by collagen stroma (HE, magnification 20 \times).

Surgical treatment of AF of head and neck is associated with high risk of complications due to the proximity of vital anatomical structures, including large blood vessels, cranial nerves and high tendency to infiltrate the surrounding tissues.¹⁰

Postoperative radiotherapy is recommended in the absence of radical removal and uncertain surgical margin.^{11,12}

Nuytens et al. analyzed data from 22 articles on the results of surgical treatment of AF and compared it with results of radiotherapy. They came to the conclusion that surgical removal of the tumor without radiotherapy led to complete recovery in 61% of cases, and when the tumor was removed with the oncological margin this percentage increased to 72%. The use of radiotherapy alone was effective in 78% of cases. Combination of surgery and radiotherapy resulted in recovery in 95% of patients.¹³




Fig. 5. Penetration of pathological cells and collagen stroma between fibers of muscle tissue (azan staining, magnification 20 \times).




Fig. 6. MRI of the neck with contrast: no evidence of tumor recurrence.

Hoos et al. concluded in a prospective study of 21 patients with AF located in head and neck region that postoperative radiotherapy in patients with positive surgical margin had no benefits compared to the results in patients treated with surgery alone. They recommended careful analysis of risk-benefit ratio of radiotherapy before treatment implementation. The most common side effects of radiotherapy include fibrosis (9.0%), paresthesia (3.0%), edema (2.2%) and fractures (2.2%).¹⁴

Own results of 203 patients with AF of head and neck region were also published in 2003 by Gronchi et al. He concluded that results of surgical treatment of the primary tumor are independent of positive or negative surgical margin and 10-year observation period without recurrence was observed in 74%–77% of patients. Based on these observations, they encourage to surgically remove AF tumors as a less invasive method maintaining function of vital organs of the head and neck.⁹

Systemic pharmacotherapy has been used in case of very advanced tumors, particularly infiltrating vital anatomical structures, and recurrences after previous surgical or radiation treatment. Treatment with non-steroid anti-inflammatory drugs may have positive effects after months of administration, though in the initial treatment period transient tumor increase was observed.¹⁵ The use of estrogen antagonists, such as tamoxifen, is based on studies that demonstrated the presence of estrogen receptors on AF cells in 33% of cases. Results of Sorensena et al. in the group of 72 patients did not confirm the presence of this receptors. The authors speculate that the efficacy of tamoxifen in some cases was associated with other causes, which have not yet been discovered.¹⁶

Chemotherapy is a rarely used treatment method in AF tumors and results presented by various authors do not clearly indicate its efficacy. Azzareli presented results of 30 patients treated with vinblastin and methotrexate. In this group, in 12 patients partial tumor regression was reported, while others did not benefit from the treatment. In other regimens the following drug combinations are used: doxorubicine, cyclophosphamide and vincristine or vincristine, actinomycin-D and cyclophosphamide. In children combination of methotrexate and vinblastine is used.¹⁷ Such treatment regimen was primarily used with no effects also in the presented case. Numerous authors emphasize the efficacy of interferon alpha (IFN) and tyrosine-kinase inhibitor (imatinib) in the treatment of AF. In vitro studies showed that these drugs may have antiproliferative effects on fibroblasts and inhibit collagen synthesis in these cells. Interferon alpha may be used in adjuvant therapy after tumor removal as a method of prevention of local recurrences. However, due to numerous side effects usually other therapeutic methods, such as radiotherapy, are used.¹⁸

In case of our patient various drugs and treatment regimens were used. He received vinblastine with methotrexate, vincristine, imatinib, tamoxifen. Despite such aggressive treatment associated with numerous side effects, no clinically significant tumor regression was observed. Only surgical tumor removal gave a chance to recovery.

5. Conclusions

1. Surgical removal of AF tumors with safe surgical margin may be in certain situations difficult, but does not significantly affect the incidence of local recurrences and should be the treatment of choice.
2. In case of very advanced lesions postoperative radiotherapy is indicated.
3. There is no convincing evidence on the efficacy of pharmacological treatment, particularly in children, thus this method should be used only in very advanced lesions and lack of consent on surgical treatment.

Conflicts of interest

None declared.

References

1. Wu C, Amini-Nik S, Nadesan P, Stanford WL, Alman BA. Aggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cells. *Cancer Res.* 2010;70(19):7690–7698.
2. Abikhzer G, Bouganim N, Finesilver A. Aggressive fibromatosis of the head and neck: case report and review of the literature. *J Otolaryngol.* 2005;34(4):289–294.
3. Goullner JR, Saul EH. Desmoid tumor: an ultrastructural study of eight cases. *Hum Pathol.* 1980;11(1):43–50.
4. Gabbiani G, Majno G. Dupuytren's contracture: fibroblast contraction? An ultrastructural study. *Am J Pathol.* 1972;66(1):131–146.
5. Burke AP, Sobin LH, Shekitka KM, Federspiel BH, Helwig EB. Intra-abdominal fibromatosis: a pathologic analysis of 130 tumors with comparison of clinical subgroups. *Am J Surg Pathol.* 1990;14(4):335–341.
6. Fasching MC, Saleh J, Woods JE. Desmoid tumors of the head and neck. *Am J Surg.* 1998;156(4):327–333.
7. Kruse AL, Luebbbers HT, Grätz KW, Obwegeser JA. Aggressive fibromatosis of the head and neck: a new classification based on a literature review over 40 years (1968–2008). *Oral Maxillofac Surg.* 2010;14(4):227–232.
8. Siegel NS, Bradford GR. Fibromatosis of the head and neck: a challenging lesion. *Otolaryngol Head Neck Surg.* 2000;123(3):269–275.
9. Gronchi A, Casali L, Mariani S, et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. *J Clin Oncol.* 2003;21(7):390–397.
10. Jelinek JA, Stelzer KJ, Conrad E, et al. The efficacy of radiotherapy as postoperative treatment for desmoid tumors. *Int J Radiat Oncol Biol Phys.* 2001;50(1):121–125.
11. Ballo MT, Zagars GK, Pollack A, Pisters PWT, Pollock RA. Desmoid tumor, prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. *J Clin Oncol.* 1999;17(1):158–167.
12. Zlotecki RA, Scarborough MT, Morris CG, et al. External beam radiotherapy for primary and adjuvant management of aggressive fibromatosis. *Int J Radiat Oncol Biol Phys.* 2002;54(1):177–181.
13. Nuyttens JJ, Rust PF, Thomas Jr CR Jr, Turrisi 3rd AT 3rd. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles. *Cancer.* 2000;88(7):1517–1523.
14. Hoos A, Lewis JJ, Urish MJ, et al. Desmoid tumors of the head and neck, a clinical study of a rare entity. *Head Neck.* 2000;22(8):814–821.
15. Waddell WR, Gerncr RE, Reich MP. Nonsteroid antiinflammatory drugs and tamoxifen for desmoid tumors and carcinoma of the stomach. *J Surg Oncol.* 1993;22(3):197–211.
16. Sørensen A, Keller J, Nielsen OS, Jensen OM. Treatment of aggressive fibromatosis: a retrospective study of 72 patients followed for 1–27 years. *Acta Orthop Scand.* 2002;73(2):213–219.
17. Azzarelli A, Gronchi A, Bertulli R, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. *Cancer.* 2001;92(5):1259–1265.
18. Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). *J Clin Oncol.* 2006;24(7):1195–1203.